GERN · XBRL financial data

Geron financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (GERN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	0	1	1	0	—	—
Selling, general and administrative	—	—	44	69	146	159
General and administrative	26	30	44	69	—	—
Total operating expenses	77	115	139	194	251	252
Operating income (loss)	(77)	(114)	(139)	(194)	(174)	(69)
Interest income	2	1	3	18	20	18
Interest expense	1	4	7	8	19	33
Other income (expense)	0	1	1	(0)	(0)	(0)
Income tax expense (benefit)	—	—	—	0	0	0
Net income (loss)	(76)	(116)	(142)	(184)	(175)	(84)
Earnings per share, basic USD per share	(0.28)	(0.35)	(0.37)	(0.32)	(0.27)	(0.13)
Earnings per share, diluted USD per share	(0.28)	(0.35)	(0.37)	(0.32)	(0.27)	(0.13)
Weighted average shares, basic millions of shares	271	328	381	571	646	667
Weighted average shares, diluted millions of shares	271	328	381	571	646	667

Fiscal years (GERN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	10	35	57	70	79	78
Marketable securities	186	149	116	264	328	—
Marketable securities, non-current	63	29	—	43	95	—
Accounts receivable	—	—	—	—	36	37
Inventory	—	—	—	—	39	117
Prepaid and other current assets	2	1	4	5	5	5
Total current assets	200	187	180	341	491	520
Property and equipment, net	1	1	1	1	1	1
Right-of-use asset	5	5	4	4	3	2
Total assets	271	226	191	394	594	571
Accounts payable	7	7	10	6	9	11
Accrued liabilities	15	30	33	40	36	51
Current portion of long-term debt	—	—	21	47	—	—
Total current liabilities	31	46	77	108	88	112
Long-term debt	24	50	30	35	118	120
Lease liability, non-current	5	4	4	3	2	1
Total liabilities	60	100	111	146	313	345
Accumulated deficit	(1,156)	(1,272)	(1,414)	(1,598)	(1,772)	(1,856)
Total stockholders' equity	211	126	80	248	280	226
Total liabilities and equity	271	226	191	394	594	571
Common shares outstanding (cover page) millions of shares	319	324	509	546	637	641

Fiscal years (GERN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(76)	(116)	(142)	(184)	(175)	(84)
Stock-based compensation	7	8	8	19	31	27
Net cash from operating activities	(67)	(96)	(127)	(168)	(219)	(111)
Purchases of property and equipment	0	0	0	1	1	—
Net cash from investing activities	(105)	72	62	(180)	(106)	107
Proceeds from issuing common stock	4	20	—	—	—	—
Proceeds from long-term debt	24	25	—	30	121	0
Repayments of long-term debt	—	—	—	0	87	0
Net cash from financing activities	168	49	87	362	334	2
Net change in cash	—	25	22	14	10	(1)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Geron	63	57	(16)*	642.5M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Intellia Therapeutics	106	7.7	(83)*	140.1M	5.3 quarters	Q2 FY26 10-QJun 30, 2026
Wave Life Sciences	197	13	(60)*	197.2M	7.4 quarters	Q3 FY26 10-QSep 30, 2026
CorMedix	257	102	86*	77.9M	—	Q2 FY26 10-QJun 30, 2026
Niagen Bioscience	67	30	2.8*	79.1M	—	Q2 FY26 10-QJun 30, 2026
Nurix Therapeutics	720	673	616*	109.2M	—	Q3 FY26 10-QAug 31, 2026
Ardelyx	46	128	2.2*	251.4M	—	Q3 FY26 10-QSep 30, 2026
Collegium Pharmaceutical	129	200	71*	32.6M	—	Q2 FY26 10-QJun 30, 2026
Syndax Pharmaceuticals	136	83	(27)*	not reported	11.9 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.